Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
Luciano Ibba,Luigi Gargiulo,Carlo Vignoli,Giovanni Fiorillo,Mario Valenti,Antonio Costanzo,Alessandra Narcisi
DOI: https://doi.org/10.2147/ccid.s329442
2024-03-13
Clinical Cosmetic and Investigational Dermatology
Abstract:Luciano Ibba, 1, 2 Luigi Gargiulo, 1, 2 Carlo Alberto Vignoli, 1, 2 Giovanni Fiorillo, 1, 2 Mario Valenti, 1, 2 Antonio Costanzo, 1, 2 Alessandra Narcisi 1 1 Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy; 2 Department of Biomedical Sciences, Humanitas University, Milan, Italy Correspondence: Luciano Ibba, Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, 20089, Italy, Email Upadacitinib is a selective Janus kinase inhibitor approved for the treatment of severe atopic dermatitis (AD). This systematic review aims to summarize the most recent data in terms of effectiveness and safety of upadacitinib in the treatment of severe AD in a real-world setting. The review included a comprehensive search of databases, including PubMed, Google Scholar and Web of Science, according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The literature search initially identified 242 studies. Of these, 214 were excluded after reviewing their titles and abstracts. We then conducted a full-text review of 25 studies, of which 17 met our inclusion criteria and were therefore included in our systematic review. The analysis of real-world studies showed high effectiveness of upadacitinib, in terms of both clinical signs and subjective symptoms, in different patient populations, including those resistant to other treatments. No new significant safety concerns have emerged as compared to randomized clinical trials. Keywords: JAKi, real-life, upadacitinib, atopic dermatitis, systematic review Atopic dermatitis (AD) is one of the most prevalent inflammatory dermatological conditions, affecting both children and adults with a significant impairment of quality of life and work productivity. 1,2 During the last ten years, the pathogenesis of AD has been deeply explored, and interleukins (ILs) such as IL-4, IL-13 and IL-31 have emerged as the pivotal cytokines in the inflammatory cascade of AD, along with barrier defects such as filaggrin mutations. 3 A better understanding of AD pathophysiology has led to the development of several new drugs that selectively target the key molecules responsible for this disease. In particular, monoclonal antibodies, which block IL-13 and IL-4 (dupilumab) or IL-13 only (tralokinumab and lebrikizumab), are currently indicated for the treatment of severe AD. 4 Another class of systemic treatments for adults with severe AD is represented by the inhibitors of Janus Kinase (JAKi), including abrocitinib, baricitinib and upadacitinib. 4 These three drugs have shown efficacy and safety in phase-III clinical trials, compared with placebo and therefore have been approved for the treatment of severe AD. 5–7 Upadacitinib and abrocitinib have also demonstrated superior rapidity and effectiveness compared with dupilumab in head-to-head clinical trials. 8–10 To date, several real-world experiences are available regarding the effectiveness and safety of upadacitinib, while only a few studies have been published on abrocitinib and baricitinib in the treatment of severe AD. 11,12 Regarding baricitinib, real-life studies have been recently published on its effectiveness also in the treatment of alopecia areata. 13,14 According to European Guidelines, both JAKi and IL inhibitors, along with cyclosporine, are recommended in adults with severe AD. 4 Abrocitinib, baricitinib, cyclosporin, dupilumab, tralokinumab and upadacitinib are all indicated as systemic treatments for severe AD in adult patients, with the same grade of recommendation, according to European Guidelines. 4 However, there is no specific indication regarding the place in therapy of JAKi, including their possible role as a first or second-line systemic treatment. Moreover, recently the Pharmacovigilance Risk Assessment Committee (PRAC) of EMA published a reassessment (EMA/PRAC/68283/2022) of the benefit–risk balance of oral JAKi, with increasing concerns regarding their safety profiles in patients with AD. 15 In addition, current guidelines do not give enough evidence on patients' management during treatment with JAKi regarding laboratory and clinical monitoring or how to handle concomitant medical procedures. In this setting, the summary of product characteristics (SmPC) of each drug can give the clinicians a little information. However, of course, these are very limited and do not cover all the possible issues that can emerge when managing these patients. 16–18 Upadacitinib, a selective JAK inhibitor primarily targeting JAK1, has been approved for the treatment of severe AD in both adolescents and adults at -Abstract Truncated-
dermatology